# 羅氏與Incyte簽訂數十億美元協議，專注於血癌及血液疾病的突破性治療。

*biotech · news · 2026-06-08 · Devdiscourse*

## Key points

- 羅氏與Nurix Therapeutics合作開發用於血癌的蛋白質降解藥物，已進入第三期臨床試驗。
- Incyte收購Vega Therapeutics，以強化其血液疾病治療管線。
- 勃林格殷格翰的肥胖藥物在臨床結果中顯著減少內臟脂肪與肝脂肪。
- 美國公共衛生官員將在世界盃期間部署廢水監測，以偵測疾病爆發。

Major developments in the pharmaceutical industry are making headlines as Roche and Incyte engage in billion-dollar agreements, focusing on groundbreaking treatments for blood cancer and blood disorders. Roche's collaboration with Nurix Therapeutics targets blood cancer using innovative protein-degrading drug technology expected to undergo phase III clinical trials. Meanwhile, U.S.-based Incyte expands its reach with the acquisition of Vega Therapeutics, aiming to bolster its pipeline of blood disorder therapies. As health innovations captivate the sector, public health officials in the U.S. are gearing up for the upcoming World Cup by employing wastewater monitoring to preempt potential disease outbreaks. Beyond these ventures, Boehringer Ingelheim's obesity drug showcases promising results, cutting visceral and liver fat significantly. This comes as the company positions itself in a competitive market. The narrative in healthcare continues to unfold with shifts in business strategies and a focus on public health protection during large-scale international events. (With inputs from agencies.)

**Companies:** Roche, Incyte, Boehringer Ingelheim, Nurix Therapeutics, Vega Therapeutics
**Countries:** United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3932038-pharma-giants-strike-cancer-and-obesity-drug-mega-deals-amidst-global-health-advancements)

---

Canonical: https://newsio.io/zh-TW/n/bebb9bb5-1c1e-4a30-a528-24fac68d6a7a/incyte
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works